Amicus Therapeutics Inc (FOLD)
HEALTH CARE:
PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases. The pharmacological chaperone technology involves the use of small molecules to restore biological activity in cells by binding to a misfolded protein caused by a genetic mutation. The company is targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Its lead compound includes Amigal, which is in Phase II clinical trials is used for the treatment of Fabry disease that causes kidney failure, cardiac abnormalities, and neurological complications. The company is also developing AT2101 for the treatment of Gaucher disease, which causes an enlarged liver and spleen, low levels of red blood cells and platelets, bone pain, and fractures; and AT2220 for the treatment of Pompe disease, which causes muscle weakness primarily affecting breathing, mobility, and heart function. The company has a strategic collaboration with Shire Human Genetic Therapies, Inc. to jointly develop pharmacological chaperone compounds for lysosomal storage disorders.
| Market Cap | 2.429 Billion | Shares Outstanding | 264.316 Million | Avg 30-day Volume | 3.172 Million | ||
| P/E Ratio | -8.77387 | Dividend Yield | EPS | -1.07 | |||
| Price/Sales | 9.31 | Debt to Equity | 3.1 | EBITDA | -235.008 Million | ||
| Price to Book Value | 8.48 | Forward PE | -10.74 | Enterprise Value | 2.335 Billion | ||
| Total Cash | 483.269 Million | Current Debt | 129.676 Million | Gross Profit | 229.842 Million | ||
| BETA | 1.11293 | 52-week High/Low | 25.39 / 8.83 | Next Earnings Date | 2021-05-06 | Price to Cash FLow (P/CF) | -9999999.0 |
| Data provided by IEX Cloud | |||||||
| Q4 2020 | All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|---|---|---|---|---|---|
| In top 10: | 6 | 6 | 0.0% | 6 (0.36%) | 6 (0.37%) | 0.0% |
| Funds Holding: | 268 | 248 | 8.06% | 90 (5.41%) | 88 (5.48%) | 2.27% |
| 13F shares: | 278.931 Million | 274.227 Million | 1.72% | 138.55 Million | 134.959 Million | 2.66% |
| % Ownership | 53.1684 | 51.7901 | 2.66% | |||
| New Positions: | 49 | 44 | 11.36% | 13 | 18 | -27.78% |
| Increased Positions | 88 | 76 | 15.79% | 25 | 31 | -19.35% |
| Closed Positions | 27 | 19 | 42.11% | 11 | 7 | 57.14% |
| Reduced Positions | 96 | 93 | 3.23% | 40 | 34 | 17.65% |
| Total Calls | 3.603 Million | 2.617 Million | 37.64% | 1.425 Million | 977 Thousand | 45.84% |
| Total Puts | 3.715 Million | 999.412 Thousand | 271.74% | 2.225 Million | 478 Thousand | 365.42% |
| PUT/CALL Ratio | 1.03 | 0.38 | 171.05% | 1.56 | 0.49 | 218.37% |
| 1 hedge funds and active managers as identified by whalewisdom.com through public filings. | ||||||
- Here are the 10 most popular hedge fund managers in WhaleWisdom. Investors react to every move they make. 03/26/2021
- Long-time Wayfair insider bought $13.6M of W on the open market. Growth to continue post-pandemic? 03/09/2021
- Hedge fund XN was one of 2020's largest new funds. Gaurav Kapadia is off to an impressive start. 03/05/2021
- While investors party like its 1999, Insiders are selling stock like there's no tomorrow. Is a crash imminent? 02/23/2021
- Hedge Funds Flock To Sea’s Stock For Future Growth Opportunities 04/12/2021
- Hedge Fund's Are Moving Into Spotify 04/05/2021
- CrowdStrike's Stock Soars Amid Global Pandemic 03/29/2021
- PayPal's Continues Upward Climb As Hedge Funds Pile In 03/22/2021
- Hedge Funds Are Still Upbeat On Slumping Qualcomm 03/15/2021
- TripAdvisor Moves Beyond Pandemic Lows 03/08/2021
